Tissue plasminogen activator for acute ischemic stroke

New England Journal of Medicine

Volumn 333, Issue 24, 1995, Pages 1581-1588

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INJURY SCALE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0028783948     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199512143332401     Document Type: Article

References (31)

1. Division of Chronic Disease Control and Community Intervention. Cardiovascular disease surveillance: stroke, 1980-1989. Atlanta: Centers for Disease Control and Prevention, 1994.
2. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91: 311-322
3. del Zoppo GJ, Poeck K, Pessin MS, Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86
4. Fletcher AP, Alkjaersig N, Lewis M, A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-142
5. Meyer JS, Gilroy J, Barnhart J. Therapeutic thrombolysis in cerebral thromboembolism: randomized evaluation of intravenous streptokinase. In: Siekert W, Whisnant JP, eds. Cerebral vascular diseases. New York: Grune & Stratton, 1965:200-13.
6. Brott TG, Haley EC Jr, Levy DE, Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640
7. Haley EC Jr, Levy DE, Brott TG, Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645
8. Pocock SJ, Geller NL, Tsiatis AA The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-498
9. Mahoney FI, Barthel DW Functional evaluation: the Barthel index. Md State Med J 1965; 14: 61-65
10. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23: 3-8 [Erratum, Stroke 1992;23:615.]
11. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607
12. Teasdale G, Knill-Jones R, van der Sande J Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 1978; 41: 603-610
13. Haley EC Jr, Kassell NF, Torner JC, A randomized controlled trial of high-dose nicardipine in aneurysmal subarachnoid hemorrhage. J Neurosurg 1993; 78: 537-547
14. Lyden P, Brott T, Tilley B, Improved reliability of the NIH Stroke Scale using video training. Stroke 1994; 25: 2220-2226
15. Albanese MA, Clarke WR, Adams HP Jr, Woolson RF Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke: the program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke 1994; 25: 1746-1751
16. Lyden PD, Broderick J, Mascha E. Reliability of the Barthel Index used for the NINDS t-PA Stroke Trial. In: Yamaguchi T, Mori E, Minematsuk K, del Zoppo GJ, eds. Thrombolytic therapy in acute stroke III. Tokyo, Japan: Springer-Verlag (in press).
17. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. 2nd ed. Littleton, Mass.: PSG Publishing, 1985.
18. Lefkopoulou M, Moore D, Ryan L The analysis of multiple correlated binary outcomes: application to rodent teratology experiments. J Am Stat Assoc 1989; 84: 810-815
19. Zeger SL, Liang KY Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130
20. Lan KKG, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663
21. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556
22. DeMets DL, Ware JH Group sequential methods for clinical trials with a one-sided hypothesis. Biometrika 1980; 67: 651-660
23. DeMets DL, Ware JH Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982; 69: 661-663
24. Haley EC Jr, Brott TG, Sheppard GL, Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993; 24: 1000-1004
25. Mori E, Yoneda Y, Tabuchi M, Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-982
26. Hacke W, Kaste M, Fieschi C, Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-1025
27. Hommel M, Boissel JP, Cornu C, Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995; 345: 57-57
28. Donnan GA, Hommel M, Davis SM, McNeil JJ Streptokinase in acute ischaemic stroke. Lancet 1995; 346: 56-56
29. Fibrinolytic Therapists Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322 [Erratum, Lancet 1994;343:742.]
30. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289-1292
31. Levy DE, Brott TG, Haley EC Jr, Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291-297